Navigation Links
Pharsight Achieves $7.4 Million in Quarterly Revenue
Date:1/24/2008

he comparable period of fiscal 2007. Excluding the impact of stock-based compensation, non-GAAP net income for the first nine months of fiscal 2008 was $2 million, 9% of revenue for the period. Net loss per basic and diluted share during the first nine months of fiscal 2008 were both $0.72 and included $0.82 in a non-cash accounting charge associated with the preferred stock conversion in the first quarter of fiscal 2008. Net income per basic and diluted share during the first nine months of fiscal 2007 were both $0.06. Non-GAAP net earnings per basic and diluted share for the first nine months of fiscal 2008 were $0.20 and $0.19 respectively and exclude the impact of stock-based compensation and the non-cash accounting charge associated with the preferred stock conversion. Non-GAAP net earnings per basic and diluted share during first nine months of fiscal 2007 were $0.16 and $0.14 and excluded the impact of stock-based compensation.

A reconciliation of GAAP to non-GAAP financial measures is included in the tables attached to this press release and on Pharsight's website under the investor relations section.

Cash & Liquidity

Pharsight exited the third fiscal quarter with cash, cash equivalents and short-term investments of $15.1 million compared with $14.7 million at the end of fiscal 2007 and $13.0 million at December 31, 2006.

Fiscal 2008 Guidance

The Company is reiterating its guidance for fiscal 2008 and has adjusted the non-GAAP diluted earnings per share guidance to reflect the Company's 1-for-3 reverse stock split effected on November 13, 2007. The updated non-GAAP diluted earnings per share is expected to be between $0.21 and $0.33, excluding the effects of the following non-cash items: approximately $0.69 related to the change in the fair value of the conversion feature of the Company's redeemable preferred stock and approximately $0.12 related to stock-based compensation expense.

"We are excited about the opportun
'/>"/>

SOURCE Pharsight Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Pharsight Announces Fiscal Third Quarter 2008 Earnings Release Date and Conference Call
2. Pharsights Reporting and Analysis Services Business Reaches Quality Assurance Milestone
3. Pharsight Signs Third WinNonlin(R) AutoPilot(TM) Customer
4. Pharsight Announces 1-For-3 Reverse Stock Split
5. Pharsight Invited to Present on Oncology Modeling and Simulation at Quantitative Pharmacology Symposium in China
6. Pharsight Invited to Present on Winning Strategies for R&D Productivity at New York Pharma Forum on October 15, 2007
7. Pharsight Hosts Fourth Annual PKS User Group Meeting
8. Pharsight Expands Strategic Consulting Services Team
9. Pharsight to Present at ROeS Seminar in Bern, Switzerland on September 10 & 11, 2007
10. Pharsight Achieves First License Sale for Public-Source Database
11. Dalton Medicinal Chemistry Partners Achieves Another Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... August 29, 2014 Due to a misstatement ... week, the Adult Stem Cell Technology Center, LLC ( ASCTC ... stem cell therapy research that might benefit ALS patients. ... for new stem cell technologies and therapeutic applications, FRC listed ... Bucket Challenge donors who wish not to support research ...
(Date:8/28/2014)... City, Ca. (PRWEB) August 28, 2014 ... E3 rating for an alcohol-based hand sanitizer, asks food ... harvest by comparing the hand sanitizer they’re currently using ... Spray . Hand hygiene is critical to fighting cross-contamination ... environment. Best Sanitizers believes there are key criteria ...
(Date:8/28/2014)... PA (PRWEB) August 28, 2014 The ... create a culture that will allow individuals to perform ... becoming increasingly important for employers looking to compete in ... industries are embracing this trend, as the sector increasingly ... of a company, which will have real results on ...
(Date:8/28/2014)... Florida State University research team has led to a ... white light, and convert photon energy directly to mechanical ... , Biwu Ma, associate professor in the Department of ... Engineering, created the molecule in a lab about a ... creation has many other unique capabilities. , For example, ...
Breaking Biology Technology:The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 3Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 3Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 3Novel 'butterfly' molecule could build new sensors, photoenergy conversion devices 2
... Exagen Diagnostics, Inc. , a specialty focused ... tests for rheumatologists and gastroenterologists, announced today the appointment ... Tornoe has more than 20 years of ... making him a key hire as Exagen broadens its ...
... LOS ANGELES, Aug. 10, 2011 Genesis Biopharma, ... cancer immunotherapies, today announced it has signed a ... National Cancer Institute (NCI).  Under the terms of ... Biopharma will work with Steven A. Rosenberg, M.D., ...
... DIEGO, Aug. 9, 2011 Verenium Corporation (Nasdaq: ... development and commercialization of high-performance enzymes, today reported a summary ... quarter and six months ended June 30, 2011. ... terms of product revenues and partnership negotiations in the first ...
Cached Biology Technology:Eric Tornoe Joins Exagen Diagnostics as President and COO 2Genesis Biopharma Signs Cooperative Research and Development Agreement With the National Cancer Institute to Develop Cancer Immunotherapies 2Genesis Biopharma Signs Cooperative Research and Development Agreement With the National Cancer Institute to Develop Cancer Immunotherapies 3Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 2Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 3Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 4Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 5Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 6Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 7Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 8Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 9
(Date:8/28/2014)... Yale University researchers have identified a handful of bacterial ... as Crohn,s disease and ulcerative colitis, using patients, own ... are published Aug. 28 in the journal Cell ... intestinal microbiota, which plays a critical role in the ... only a small number of bacterial species affect a ...
(Date:8/28/2014)... FASEB MARC (Maximizing Access to Research Careers) Program has ... of Human Genetics from October 18 22, 2014 ... to promote the entry of students, post doctorates and ... basic science community and to encourage the participation of ... This year MARC conferred 16 awards totaling $29,600., ...
(Date:8/28/2014)... The support of peer groups and clinicians ... programs, according to recent University of Georgia research. ... the Athens-Clarke County area determined that role models ... of mothers of infants. , "Mothers who received ... at breastfeeding," said study co-author Alex Anderson, an ...
Breaking Biology News(10 mins):Yale study identifies possible bacterial drivers of IBD 2Breastfeeding study shows need for effective peer counseling programs 2
... is available in German . , ... species of the Galapagos archipelago, treks slowly and untiringly ... Institute for Ornithology in Radolfzell, together with the Charles ... acceleration measurements to find out that especially the dominant ...
... A study published in the current issue ... available on-line at http://www.ingentaconnect.com/content/cog/ct/ , has found ... (SM-MSCs) or adipose tissue (ADSCs) were injected into ... laboratory rats that had suffered a myocardial infarction, ...
... more than 200 million people every year mainly in ... the Plasmodium parasite, which is spread by infected ... but more than half a million people nevertheless die every ... during the past decade have reduced the distribution of the ...
Cached Biology News:Galapagos tortoises are a migrating species 2Galapagos tortoises are a migrating species 3Study suggests different organ-derived stem cell injections improve heart function 2New method for diagnosing malaria 2
... performance for all vacuum requirements. A 3 ... to suit all applications. The large, sideview ... proper oil levels at a glance. The ... work with all Thermo Savant SpeedVac concentrating ...
... used to assess the effect of drugs on ... and rats using one unit in a safe ... are placed on textured drums to avoid slipping. ... platforms below, its test results are recorded. • ...
... 8-iso-13,14-dihydro-15-keto Prostaglandin F2α (8-iso-13,14-dihydro-15-keto PGF2α) ... 8-isoprostane (8-iso PGF2α), in rabbits, monkeys ... PG-like product of non-specific lipid peroxidation. ... infused 8-isoprostane is converted primarily to ...
... 3C protease from human rhinovirus (HRV 3C) ... brand line of restriction grade proteases. The ... 6XHis-fusion protein, which recognizes the same cleavage ... small, 22 KDa size of the protease, ...
Biology Products: